Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.

MLA

Barun, Barbara, et al. “Influence of Delaying Ocrelizumab Dosing in Multiple Sclerosis Due to COVID-19 Pandemics on Clinical and Laboratory Effectiveness.” Multiple Sclerosis and Related Disorders, vol. 48, Feb. 2021, p. 102704. EBSCOhost, https://doi.org/10.1016/j.msard.2020.102704.

APA

Barun, B., Gabelić, T., Adamec, I., Babić, A., Lalić, H., Batinić, D., Krbot Skorić, M., & Habek, M. (2021). Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Multiple Sclerosis and Related Disorders, 48, 102704. https://doi.org/10.1016/j.msard.2020.102704

Chicago

Barun, Barbara, Tereza Gabelić, Ivan Adamec, Antonija Babić, Hrvoje Lalić, Drago Batinić, Magdalena Krbot Skorić, and Mario Habek. 2021. “Influence of Delaying Ocrelizumab Dosing in Multiple Sclerosis Due to COVID-19 Pandemics on Clinical and Laboratory Effectiveness.” Multiple Sclerosis and Related Disorders 48 (February): 102704. doi:10.1016/j.msard.2020.102704.